7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
A clinician-reviewed guide to suvorexant pharmacogenomics, ethnicity-stratified trial data, and practical dose-adjustment guidance for Hispanic / Latino patients prescribed Belsomra.
Evidence review of suvorexant (Belsomra) efficacy in South Asian populations, covering CYP3A4 pharmacogenomics, BMI-adjusted dosing, and ethnicity-stratified trial data.
Evidence-based review of suvorexant (Belsomra) pharmacogenomics, dosing considerations, and safety data relevant to Black and African ancestry populations.
Evidence-based review of suvorexant pharmacogenomics, CYP3A4 metabolism, and dosing considerations specific to Hispanic and Latino populations, including diabetes comorbidity data and ethnicity-stratified trial results.
Evidence-based review of how suvorexant (Belsomra) safety, metabolism, and dosing may differ in South Asian populations due to pharmacogenomic variation, body composition, and CYP3A4 polymorphisms.
A clinical review of suvorexant (Belsomra) efficacy differences in East Asian patients, covering CYP3A4/CYP2C19 pharmacogenomics, ethnicity-stratified trial data, FDA-approved dosing adjustments, and prescribing guidance.
A clinical review of suvorexant (Belsomra) efficacy and pharmacogenomic differences in Hispanic and Latino patients, including CYP3A4 variation, orexin receptor biology, and dosing considerations relevant to this population.